| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
SIRT2 (EC50 = 2 μM); SIRT1 (EC50 = 50~180 μM)
|
|---|---|
| ln Vitro |
In A375 and SK-MEL-28 cells, nicotinamide hydrochloride (0–50 mM, 24/48 hours) decreases the number of cells in a time- and dose-dependent manner [1]. A375 cells accumulate in the G1 phase, decrease in the S phase, and rise in the sub-G1 phase (cell disinfection) when exposed to nicotinamide hydrochloride (10–50 mM) for 24 hours [1]. In A375 and SK-MEL-28 cells, nicotinamide hydrochloride (1–50 mM, 6 hours) raises NAD. In vitro, nicotinamide hydrochloride (0.01–20 mM, 1 hour) suppresses SIRT2 enzyme activity with an EC50 of 2 μM[1]. HepAD38 HBV, ATP, and ROS levels are inhibited by nicotinamide hydrochloride (0–64 mM) [1]. By suppressing CK1 and ROCK, nicotinamide hydrochloride (10 mM, day 13) enhances cell multiplication from human blood stem cell (hESC) cells [4].
|
| ln Vivo |
Nicotinamide hydrochloride (ip, 1500 and 1800 mg/Kg, 5 days per week) interferes with tumor growth in melanoma animals [1]. Nicotinamide hydrochloride (ip, 1800 mg/Kg, once daily, mouse model of metastatic melanoma) affects IFN-γ, a key mediator of cell-mediated anti-tumor immunity, and increases TNF levels of Eotaxin and IL-5 , Reduce TNF levels of IL-3, IL-12, RANTES and IL-10 Nicotinamide hydrochloride (intravenous injection, 0-200 mg/kg, 5 days) inhibits HBV replication in the center of the HBV switch button [3].
|
| Cell Assay |
Cell viability assay[1]
Cell Types: Replication in HepG2.2.15 cells[3]. A375, SK-MEL-28, mouse B16-F10 Cell Tested Concentrations: 0, 1, 20, 50 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Cell number diminished in a dose-dependent manner, with strong effects at 20mM and 20mM Inhibition is almost complete at 50 mM. Cell cycle analysis[1] Cell Types: A375, SK-MEL-28 Tested Concentrations: 10, 20, 50 mM Incubation Duration: 24 hrs (hours) Experimental Results: A375 cells arrested in G1 phase. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice (subcutaneous injection of B16-F10 cells) [1]. 1]
Doses: 1000, 1500, 1800 mg/kg. Route of Administration: intraperitoneal (ip) injection, 5 days per week (followed by 2 days off) or one time/day. Experimental Results: 1500 and 1800 mg/Kg inhibited tumor growth and had no effect on body weight. Increases the frequency of IFN-γ-producing cells and modulates protein levels of cytokines and chemokines in the plasma of tumor-bearing mice. Animal/Disease Models: HBV transgenic mice [3] Doses: 0-200 mg/kg Route of Administration: intravenous (iv) (iv)injection, 5 days Experimental Results: Reduction of serum HBV DNA. |
| References |
|
| Molecular Formula |
C6H6N2O.HCL
|
|---|---|
| Exact Mass |
158.025
|
| Elemental Analysis |
C, 45.44; H, 4.45; Cl, 22.35; N, 17.66; O, 10.09
|
| CAS # |
25334-23-0
|
| Related CAS # |
Nicotinamide;98-92-0
|
| PubChem CID |
91408
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
334.4ºC at 760mmHg
|
| Flash Point |
156ºC
|
| Vapour Pressure |
0.000128mmHg at 25°C
|
| LogP |
1.682
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
114
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC(C1=CN=CC=C1)=O.Cl
|
| InChi Key |
OBLVPWTUALCMGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6N2O.ClH/c7-6(9)5-2-1-3-8-4-5;/h1-4H,(H2,7,9);1H
|
| Chemical Name |
pyridine-3-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
